Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
François‐Xavier Mahon(Inserm), Delphine Réa(Hôpital Saint-Louis), Joëlle Guilhot(Inserm), François Guilhot(Centre Hospitalier Universitaire de Poitiers), Françoise Huguet(Hôpital Purpan), Franck E. Nicolini(Hôpital Edouard Herriot), Laurence Legros(Centre Hospitalier Universitaire de Nice), Aude Charbonnier(Institut Paoli-Calmettes), Agnès Guerci(Centre Hospitalier Régional et Universitaire de Nancy), Bruno Varet(Hôpital Necker-Enfants Malades), Gabriel Étienne(Institut Bergonié), Josy Reiffers(Institut Bergonié), Philippe Rousselot(Inserm)
Cited by 1,535
Abstract
Related Papers
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Stephen G. O’Brien, François Guilhot, Richard A. Larson et al.|New England Journal of Medicine|2003|3.6k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al.|New England Journal of Medicine|2002|2k